
A BILL FOR AN ACT

RELATING TO PSILOCYBIN.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. The legislature finds that there is heightened
2 awareness of the detrimental effects of untreated and maltreated
3 mental health in our population. With a shortage of mental
4 health professionals and appropriate mental health care, the
5 State must actively consider innovative and effective treatment
6 options to address this pressing need.

7 The legislature further finds that psilocybin has been
8 found to be very effective in treating a variety of mental
9 health conditions, including but not limited to post-traumatic
10 stress disorder, depression, anxiety, and end-of-life
11 psychological distress. As a result, the United States Food and
12 Drug Administration has designated treatment that uses
13 psilocybin in a therapeutic manner for treatment resistant
14 depression as a "breakthrough therapy".

15 The legislature also finds that at least two states, Oregon
16 and Colorado, have found that legalizing medicinal psilocybin is



1 a valuable tool in dealing with various mental health
2 conditions.

3 Accordingly, the purpose of this Act is to establish the
4 therapeutic psilocybin working group to:

5 (1) Examine the medicinal and therapeutic effects of
6 psilocybin or psilocybin-based products vis-à-vis
7 mental health including post-traumatic stress
8 disorder, depression, anxiety, and end-of-life
9 psychological distress;

10 (2) Examine the effectiveness of medicinal and therapeutic
11 uses of psilocybin or psilocybin-based products in
12 treating mental health in the two states that have
13 legalized medicinal psilocybin, Oregon and Colorado;
14 and

15 (3) To determine and develop a long-term strategic plan to
16 ensure the safe availability and accessibility of
17 affordable, therapeutic psilocybin or psilocybin-based
18 products for adults twenty-one years of age or older.

19 SECTION 2. (a) There is established a therapeutic
20 psilocybin working group within the department of health for
21 administrative purposes.



- 1 (b) The working group shall:
- 2 (1) Examine federal, state, and local laws, regulations,
- 3 administrative rules, and procedures regarding the
- 4 therapeutic use of psilocybin;
- 5 (2) Examine medical, psychological, and scientific
- 6 studies, research, and other information relating to
- 7 the efficacy and safety of psilocybin or psilocybin-
- 8 based products in treating mental health disorders,
- 9 including post-traumatic stress disorder, depression,
- 10 anxiety, and end-of-life psychological distress;
- 11 (3) Examine existing laws, requirements, and guidelines in
- 12 jurisdictions in which psilocybin or psilocybin-based
- 13 products is legally used to treat mental health
- 14 conditions; and
- 15 (4) If appropriate, determine and develop a long-term
- 16 strategic plan to ensure the safe availability and
- 17 accessibility of affordable, therapeutic psilocybin or
- 18 psilocybin-based products for adults twenty-one years
- 19 of age or older.
- 20 (c) The working group shall consist of the following
- 21 individuals:



- 1 (1) The director of health, or the director's respective
2 designee, who shall serve as chairperson of the
3 working group;
- 4 (2) The attorney general, or the attorney general's
5 respective designee;
- 6 (3) The dean of the John A. Burns school of medicine at
7 the University of Hawaii at Manoa, or the dean's
8 respective designee;
- 9 (4) The chairpersons of the health and the judiciary
10 standing committees within the senate and house of
11 representatives, or the respective designees of the
12 health and the judiciary standing committees within
13 the senate and house of representatives as appointed
14 by the senate president and the speaker of the house
15 of representatives;
- 16 (5) The chairperson of the Hawaii state council on mental
17 health, or the chairperson's respective designee;
- 18 (6) A physician duly licensed pursuant to chapter 453,
19 Hawaii Revised Statutes, or an advanced practice
20 registered nurse who is authorized to prescribe
21 psychotropic medication and is duly licensed pursuant



1 to chapter 457, Hawaii Revised Statutes, as invited by
2 the chairperson of the working group;

3 (7) A psychiatrist duly licensed pursuant to chapter 453,
4 Hawaii Revised Statutes, as invited by the chairperson
5 of the working group; and

6 (8) Other interested parties with relevant experience and
7 expertise, as invited by the chairperson of the
8 working group.

9 (d) The members of the working group shall serve without
10 compensation but shall be reimbursed for expenses, including
11 travel expenses, necessary for the performance of their duties.
12 No member of the working group shall be subject to chapter 84,
13 Hawaii Revised Statutes, solely because of the member's
14 participation in the working group.

15 (e) The working group shall submit a report of its
16 findings and recommendations, including any proposed
17 legislation, to the legislature no later than twenty days prior
18 to the convening of the regular session of 2024.


19 (f) The working group shall be dissolved on June 30, 2025.



1 SECTION 3. This Act shall take effect upon its approval.

2

INTRODUCED BY:



JAN 25 2023



H.B. NO. 1337

Report Title:

Psilocybin; Department of Health; Working Group; Report

Description:

Establishes the Therapeutic Psilocybin Working Group.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

